相关实验视频

Updated: Jul 27, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.5K

以测量为指导的治疗剂量预测,使用体积调制弧线放射治疗的多层封闭模式融合模型

Changfei Gong1,2,3, Yuling Huang1,2,3, Junming Jian1,2,3

  • 1Department of Radiation Oncology, Jianxi Center Hospital & Institute, Nanchang, Jiangxi, China.

Frontiers in oncology
|April 3, 2025
PubMed
概括

这项研究引入了一种新的深度学习模型,用于预测头癌患者的治疗辐射剂量. 人工智能模型增强了无测量预治疗患者特定质量保证 (prePSQA),以提高准确性和安全性.

关键词:
人工智能的人工智能是人工智能.多层封闭模式融合网络多层封闭模式融合网络在治疗前,患者特异性质量保证.辐射疗法 辐射疗法治疗剂量预测的预测

更多相关视频

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.4K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

相关概念视频

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).